KalVista Pharmaceuticals, Inc.
KALV
$11.85
$0.100.85%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -34.90% | -16.78% | -4.48% | 10.42% | 14.84% |
| Gross Profit | 36.43% | 16.78% | 4.48% | -10.42% | -14.84% |
| SG&A Expenses | 130.89% | 114.24% | 158.33% | 129.72% | 92.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.27% | 33.86% | 46.64% | 46.05% | 36.88% |
| Operating Income | -30.36% | -33.86% | -46.64% | -46.05% | -36.88% |
| Income Before Tax | -39.35% | -42.17% | -58.47% | -55.49% | -48.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.26% | -44.85% | -62.39% | -55.49% | -48.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.26% | -44.85% | -62.39% | -55.49% | -48.95% |
| EBIT | -30.36% | -33.86% | -46.64% | -46.05% | -36.88% |
| EBITDA | -30.44% | -33.97% | -46.85% | -46.28% | -37.05% |
| EPS Basic | -11.31% | -8.55% | -18.75% | -19.16% | -11.87% |
| Normalized Basic EPS | -8.29% | -6.42% | -15.97% | -19.23% | -12.81% |
| EPS Diluted | -11.31% | -8.55% | -18.75% | -19.16% | -11.87% |
| Normalized Diluted EPS | -8.29% | -6.42% | -15.97% | -19.23% | -12.81% |
| Average Basic Shares Outstanding | 29.39% | 34.84% | 37.02% | 30.12% | 30.82% |
| Average Diluted Shares Outstanding | 29.39% | 34.84% | 37.02% | 30.12% | 30.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |